[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561964":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":44,"responsibleParty":248,"collaborators":40,"id":250,"slug":251,"hasResults":252,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":252,"sex":258,"minAge":259,"maxAge":260,"enrollmentInfo":261,"targetDuration":40,"studyType":264,"phases":265,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":47,"whyStopped":40,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":294},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Inclisiran","EXPERIMENTAL","Year 1 - inclisiran sodium subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium subcutaneous injection (given at Days 450 and 630)",[13],"Drug: Inclisiran",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium subcutaneous injection (given at Days 360, 450, and 630)",[19],"Drug: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg, inclisiran sodium 180 mg s.c. for participants with body weight \\\u003C23 kg to ≥16 kg, or inclisiran sodium 100 mg s.c. for participants with body weight \\\u003C16 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.",[9],[26],"KJX839",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)",[15],[31],"saline solution",[33],{"name":34,"affiliation":34,"role":35},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[37,42],{"name":34,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","1-888-669-6682",null,"novartis.email@novartis.com",{"name":34,"role":38,"phone":43,"phoneExt":40,"email":40},"+41613241111",[45,67,76,93,109,120,131,142,152,160,171,182,193,203,211,221,230,238],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"UC San Francisco Medical Center","RECRUITING","San Francisco","California","94143","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-122.41942,37.77493,{"lat":57,"lon":56},[60,64],{"name":61,"role":38,"phone":62,"phoneExt":40,"email":63},"Luis Gay","+1 415 990 7296","Luis.Gay@ucsf.edu",{"name":65,"role":66,"phone":40,"phoneExt":40,"email":40},"Martin Thelin","PRINCIPAL_INVESTIGATOR",{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":68,"geoPoint":70,"contacts":71},{"type":54,"coordinates":69},[56,57],{"lat":57,"lon":56},[72,75],{"name":61,"role":38,"phone":73,"phoneExt":40,"email":74},"+1 415 476 8338","luis.gay@ucsf.edu",{"name":65,"role":66,"phone":40,"phoneExt":40,"email":40},{"facility":77,"status":47,"city":78,"state":79,"zip":80,"country":51,"countryCode":52,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Childrens National Hospital","Washington D.C.","District of Columbia","20010",{"type":54,"coordinates":82},[83,84],-77.03637,38.89511,{"lat":84,"lon":83},[87,91],{"name":88,"role":38,"phone":89,"phoneExt":40,"email":90},"Desiree Tobechukwu Nwanze","+1 202 476 5000","dnwanze@childrensnational.org",{"name":92,"role":66,"phone":40,"phoneExt":40,"email":40},"Sarah Clauss",{"facility":94,"status":47,"city":95,"state":96,"zip":97,"country":51,"countryCode":52,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Washington Univ School Of Medicine","St Louis","Missouri","63110",{"type":54,"coordinates":99},[100,101],-90.19789,38.62727,{"lat":101,"lon":100},[104,107],{"name":105,"role":38,"phone":40,"phoneExt":40,"email":106},"Jodi Pagano","jpagano@wustl.edu",{"name":108,"role":66,"phone":40,"phoneExt":40,"email":40},"Anne Goldberg",{"facility":110,"status":47,"city":111,"state":40,"zip":112,"country":113,"countryCode":114,"cosmosGeoPoint":115,"geoPoint":119,"contacts":40},"Novartis Investigative Site","Vienna","1090","Austria","AT",{"type":54,"coordinates":116},[117,118],16.37208,48.20849,{"lat":118,"lon":117},{"facility":110,"status":47,"city":121,"state":122,"zip":123,"country":124,"countryCode":125,"cosmosGeoPoint":126,"geoPoint":130,"contacts":40},"Beijing","Beijing Municipality","100013","China","CN",{"type":54,"coordinates":127},[128,129],116.39723,39.9075,{"lat":129,"lon":128},{"facility":110,"status":47,"city":132,"state":133,"zip":134,"country":135,"countryCode":136,"cosmosGeoPoint":137,"geoPoint":141,"contacts":40},"Frankfurt am Main","Hesse","60590","Germany","DE",{"type":54,"coordinates":138},[139,140],8.68417,50.11552,{"lat":140,"lon":139},{"facility":110,"status":47,"city":143,"state":40,"zip":144,"country":145,"countryCode":146,"cosmosGeoPoint":147,"geoPoint":151,"contacts":40},"Ioannina","455 00","Greece","GR",{"type":54,"coordinates":148},[149,150],20.85187,39.66341,{"lat":150,"lon":149},{"facility":110,"status":47,"city":153,"state":40,"zip":154,"country":145,"countryCode":146,"cosmosGeoPoint":155,"geoPoint":159,"contacts":40},"Thessaloniki","546 42",{"type":54,"coordinates":156},[157,158],22.93493,40.64072,{"lat":158,"lon":157},{"facility":110,"status":47,"city":161,"state":162,"zip":163,"country":164,"countryCode":165,"cosmosGeoPoint":166,"geoPoint":170,"contacts":40},"Kota Bharu","Kelantan","16150","Malaysia","MY",{"type":54,"coordinates":167},[168,169],102.24333,6.12361,{"lat":169,"lon":168},{"facility":110,"status":47,"city":172,"state":173,"zip":174,"country":175,"countryCode":176,"cosmosGeoPoint":177,"geoPoint":181,"contacts":40},"Amsterdam","North Holland","1105 AZ","Netherlands","NL",{"type":54,"coordinates":178},[179,180],4.88969,52.37403,{"lat":180,"lon":179},{"facility":110,"status":47,"city":183,"state":184,"zip":185,"country":186,"countryCode":187,"cosmosGeoPoint":188,"geoPoint":192,"contacts":40},"Bloemfontein","Free State","9301","South Africa","ZA",{"type":54,"coordinates":189},[190,191],26.214,-29.12107,{"lat":191,"lon":190},{"facility":110,"status":47,"city":194,"state":40,"zip":195,"country":196,"countryCode":197,"cosmosGeoPoint":198,"geoPoint":202,"contacts":40},"Taichung","407219","Taiwan","TW",{"type":54,"coordinates":199},[200,201],120.6839,24.1469,{"lat":201,"lon":200},{"facility":110,"status":47,"city":204,"state":40,"zip":205,"country":196,"countryCode":197,"cosmosGeoPoint":206,"geoPoint":210,"contacts":40},"Taipei","111045",{"type":54,"coordinates":207},[208,209],121.52639,25.05306,{"lat":209,"lon":208},{"facility":110,"status":47,"city":212,"state":213,"zip":214,"country":215,"countryCode":40,"cosmosGeoPoint":216,"geoPoint":220,"contacts":40},"Adana","Saricam","01330","Turkey (Türkiye)",{"type":54,"coordinates":217},[218,219],35.32531,36.98615,{"lat":219,"lon":218},{"facility":110,"status":47,"city":222,"state":223,"zip":224,"country":215,"countryCode":40,"cosmosGeoPoint":225,"geoPoint":229,"contacts":40},"Ankara","Yenimahalle","06500",{"type":54,"coordinates":226},[227,228],32.85427,39.91987,{"lat":228,"lon":227},{"facility":110,"status":47,"city":231,"state":40,"zip":232,"country":215,"countryCode":40,"cosmosGeoPoint":233,"geoPoint":237,"contacts":40},"Izmir","35100",{"type":54,"coordinates":234},[235,236],27.13838,38.41273,{"lat":236,"lon":235},{"facility":110,"status":47,"city":239,"state":40,"zip":240,"country":241,"countryCode":242,"cosmosGeoPoint":243,"geoPoint":247,"contacts":40},"Southampton","SO16 6YD","United Kingdom","UK",{"type":54,"coordinates":244},[245,246],-1.40428,50.90395,{"lat":246,"lon":245},{"type":249,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100561964","phase-3-study-to-evaluate-safety-tolerability-and-efficacy-of-inclisiran-in-children-with-homozygous-familial-hypercholesterolemia-100561964",false,"NCT06597006","Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia","Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Children (2 to Less Than 12 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol","ORION-19","Inclusion Criteria:\n\n* Male or female participants, 2 to \\\u003C12 years of age at screening\n* HoFH diagnosed by genetic confirmation\n\n  \\- Note: Participants with known null (negative) mutations in both LDLR alleles are not eligible (see also exclusion criteria)\n* Fasting LDL-C \\>130 mg\u002FdL (3.4 mmol\u002FL) at screening\n* On an optimal dose of statin (investigator's discretion), unless statin intolerant, with or without other lipid-lowering therapy (e.g. ezetimibe)\n* Participants on lipid-lowering therapies (such as e.g. statins, ezetimibe) must be on a stable dose for ≥30 days before screening with no planned medication or dose changes during study participation\n* Participants on a documented regimen of LDL-apheresis for ≥ 3 months before screening will be allowed to continue the apheresis during the study, if needed. The apheresis schedule\u002Fsettings\u002Fduration must be stable prior to screening, are not allowed to change during the double-blind period of the trial and must permit that an apheresis coincides with each study visit.\n\nExclusion Criteria:\n\n* Documented evidence of a null (negative) mutation in both LDLR alleles\n* Previous treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9\n* History of poor response to therapy with any monoclonal antibody directed towards PCSK9 (e.g. \\\u003C15% reduction in LDL-C)\n* Treatment with mipomersen or lomitapide (within 5 months of screening)\n* Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome\n* Heterozygous familial hypercholesterolemia (HeFH)\n* Body weight (at the screening and\u002For randomization (Day 1) visit) \\\u003C16 kg for participants 6 to \\\u003C12 years (at screening) or \\\u003C11 kg for participants 2 to \\\u003C6 years (at screening)\n* Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST) elevation \\>3x ULN, or total bilirubin elevation \\>2x ULN (except patients with Gilbert's syndrome)\n* Pregnant or nursing females\n* Recent and\u002For planned use of other investigational medicinal products or devices","ALL","2 Years","11 Years",{"count":262,"type":263},9,"ESTIMATED","INTERVENTIONAL",[266],"PHASE3","This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to \\\u003C12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDLC).",[269],"Familial Hypercholesterolemia - Homozygous",[271,272,273,274,275,276,277,278,279,280,281,282,283,284],"Homozygous familial hypercholesterolemia (HoFH),","LDL-cholesterol (LDL-C), children, pediatric,","small interfering ribonucleic acid (siRNA),","inclisiran,","Familial Hypercholesterolemia,","Homozygous FH,","Hypercholesterolemia,","Lipoprotein(a),","Hyperlipidemia,","Dyslipidemia,","Cardiovascular Diseases,","Heart Failure,","Cholesterol,","Aortic Stenosis","2026-02-18",{"date":287,"type":288},"2026-02-20","ACTUAL",{"date":290,"type":288},"2025-02-28",{"date":292,"type":263},"2029-04-15",{"name":34,"class":6},18]